Ignite Creation Date:
2025-12-25 @ 2:22 AM
Ignite Modification Date:
2026-01-07 @ 4:09 AM
Study NCT ID:
NCT06597734
Status:
RECRUITING
Last Update Posted:
2025-10-09
First Post:
2024-09-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-01-28
Start Date Type:
ACTUAL
Primary Completion Date:
2027-08-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-08-31
Completion Date Type:
ESTIMATED
First Submit Date:
2024-09-12
First Submit QC Date:
None
Study First Post Date:
2024-09-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-07
Last Update Post Date:
2025-10-09
Last Update Post Date Type:
ESTIMATED